杂志简称：j diabetes
中文译名：《糖尿病杂志》
收录属性：高质量科技期刊（t3）, scie（2024版）, 目次收录（维普）,英文期刊,
自引率：4.00%
投稿方向：医学、endocrinology & metabolism 内分泌学与代谢
SCI/E期刊基本信息
出版周期：月刊 地区：中国
中科院分区：2区
是否TOP：非TOP期刊
是否综述：非综述期刊
是否OA：非OA期刊
国际标准刊号：ISSN1753-0393；EISSN1753-0407
杂志语言：英语
出版国家：中国
杂志官网 联系方式
出版地址：111 RIVER ST,HOBOKEN,USA,NJ,07030-5774
杂志邮箱：
投稿网址：http://mc.manuscriptcentral.com/jdb
杂志官方网址：https://onlinelibrary.wiley.com/journal/17530407
出版商网址：http://www.wiley.com/WileyCDA/
杂志投稿要求
投稿须知【杂志社官方网站信息】
Author Guidelines
1. MANUSCRIPT SUBMISSION
Thank you for your interest in Journal of Diabetes. Please read the complete Author Guidelines carefully prior to submission. Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium.
Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at http://mc.manuscriptcentral.com/jdb.
The submission system will prompt you to use an ORCiD (a unique author identifier) to help distinguish your work from that of other researchers. Click here to find out more.
Click here for more details on how to use ScholarOne.
We are looking forward to your submission.
Preprints
Journal of Diabetes will not consider submissions that have previously been made available online, either on a preprint server like arXiv, bioRxiv, or PeerJ PrePrints, or on the authors’ own website., or have been published in a scientific journal, book or other venue that could be considered formal publication. Authors must inform the editorial office at submission if their paper has been made available as a preprint or have otherwise been previously published.
2. EDITORIAL CONSIDERATIONS
Aims and Scope
Journal of Diabetes (JDB) devotes itself to diabetes research, therapeutics, and education. It aims to involve researchers and practitioners in a dialogue between East and West via all aspects of epidemiology, etiology, pathogenesis, management, complications and prevention of diabetes, including the molecular, biochemical, and physiological aspects of diabetes. The Editorial team is international with a unique mix of Asian and Western participation.
The Editors welcome submissions in form of original research articles, images, novel case reports and correspondence, and we solicit reviews, point-counterpoint, commentaries, editorials, news highlights, and educational content.
Effective with the 2017 volume, this journal will be published in an online-only format.
Print subscription and single issue sales are available from Wiley’s Print-on-Demand Partner. To order online click through to the ordering portal from the journal’s subscribe and renew page on WOL.
Review Process
Manuscripts are assigned sequentially to Associate Editors. An Associate Editor solicits reviewers (typically, two external reviews are sought). The reviewers’ evaluations and Associate Editor’s comments are compiled by the Editor-in-Chief for disposition and transmittal to the authors. A decision is made usually within six weeks of the receipt of the manuscript.
The Editor-in-Chief will advise authors whether a manuscript is accepted, should be revised or is rejected. Minor revisions are expected to be returned within four weeks of decision; major revisions within three months. Manuscripts not revised within these time periods are subject to withdrawal from consideration for publication unless the authors can provide extenuating circumstances.
A number of manuscripts will have to be rejected on the grounds of priority and available space. A manuscript may be returned to the authors without outside review if the Editor-in-Chief and Associate Editor find it inappropriate for publication in the Journal. Similarly, the Editors may expedite the review process for manuscripts felt to be of high priority in order to reach a rapid decision. Such ‘fast-track decisions’ will normally occur within one week of receipt of the manuscript.
The Editor-in-Chief’s decision is final. If, however, authors dispute a decision and can document good reasons why a manuscript should be reconsidered, a rebuttal process exists. In the first place, authors should write to the Editor-in-Chief.
3. ETHICAL CONSIDERATIONS
Authorship and Acknowledgements
The journal adheres to the definition of authorship set up by The International Committee of Medical Journal Editors (ICMJE). The ICMJE recommends that authorship be based on the following 4 criteria: i) Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; ii) Drafting the work or revising it critically for important intellectual content; iii) Final approval of the version to be published; and iv) Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Contributors who do not qualify as authors should be mentioned under ‘Acknowledgements’.
The journal accepts up to three corresponding authors, but please appoint one as the main contact to communicate with editors.
Disclosure
At the time of submission, the submitting author must include a disclosure statement in the body of the manuscript. All authors are required to disclose all potential conflicts of interest, including specific financial interests and relationships and affiliations (other than those affiliations listed in the title page of the manuscript) relevant to the subject of their manuscript. This information should be provided under the heading titled ‘Disclosure,’ which should appear after the ‘Acknowledge’ section and before the ‘References’ section. Authors without conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject of their manuscript, should include a statement of no such interests in the Disclosure section of the manuscript. Failure to include this information in the manuscript may delay evaluation and review of the manuscript. The conflict of interest policy for the Editors is available on the journal's Editors Conflict Guidelines.
Principles for Publication of Research Involving Human Subjects
Manuscripts must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the Declaration of Helsinki (as revised in Brazil 2013), available at https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. It should also state clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under the study should be omitted. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used).
In general, submission of a case report should be accompanied by the written consent of the subject (or parent/guardian) before publication; this is particularly important where photographs are to be used or in cases where the unique nature of the incident reported makes it possible for the patient to be identified. While the Editorial Board recognizes that it might not always be possible or appropriate to seek such consent, the onus will be on the authors to demonstrate that this exception applies in their case.
Any experiments involving animals must be demonstrated to be ethically acceptable and must conform to international guidelines for animal usage in research, such as those of the US NIH or the UK Home Office.
Clinical Trials Registry
We require, as a condition of consideration for publication, registration in a public trials registry. Trials must register at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after January 1, 2006. For trials that began enrollment before this date, we require registration by April 1, 2006, before considering the trial for publication. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes, such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials) are exempt.
We do not advocate one particular registry, but registration must be with a registry that meets the following minimum criteria: (1) accessible to the public at no charge; (2) searchable by standard, electronic (Internet-based) methods; (3) open to all prospective registrants free of charge or at minimal cost; (4) validates registered information; (5) identifies trials with a unique number; and (6) includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s).
Registries that currently meet these criteria include: (1) the registry sponsored by the United States National Library of Medicine; (2) the International Standard Randomized Controlled Trial Number Registry; (3) the Australian New Zealand Clinical Trials Registry (ANZCTR); (4) the Chinese Clinical Trials Registry; and (5) the Clinical Trials Registry – India.
Randomized control trials
Reporting of randomized controlled trials should follow the guidelines of The CONSORT Statement, and the CONSORT Checklist is required to be uploaded as supplementary information during submission.
Reproduction of Copyright Material. If excerpts from copyrighted works owned by third parties are included, credit must be shown in the contribution. It is the author’s responsibility to also obtain written permission for reproduction from the copyright owners. For more information visit Wiley’s Copyright Terms & Conditions FAQ at http://exchanges.wiley.com/authors/faqs—copyright-terms–conditions-301.html
Plagiarism Detection. The journal employs a plagiarism detection system. By submitting your manuscript to this journal you accept that your manuscript may be screened for plagiarism against previously published works.
Committee on Publication Ethics. The journal is a member of, and subscribes to the principles of the Committee on Publication Ethics (COPE).
4. MANUSCRIPT CATEGORIES
(1) Original Articles
●Word limit: 4,000 words maximum including abstract but excluding the highlights of the study (see 5. PREPARATION OF THE MANUSCRIPT, under Highlights), references, tables and figures.
●Abstract: 250 words maximum, with sub-headers.
●References: no limit.
●Figures/ tables: no limit, but 8 figures should be sufficient, excluding the feature figure (see 5. PREPARATION OF THE MANUSCRIPT, under Feature Figure).
●Description: Full-length reports of current research in either basic or clinical science.
(2) Case Reports
●Word limit: 1,000 words maximum excluding references, tables and figures.
●Abstract: not required.
●References: no limit.
●Figures/ tables: 4 maximum.
●Description: New observations of diseases, clinical findings or novel/unique treatment outcomes relevant to practitioners in diabetes. The text should be arranged as follows: Introduction; Case Report; Discussion. Such cases would be expected to illustrate highly unusual demonstrations of diabetes-related principals, such as genetic or hormonal variations, which would not be expected to occur with sufficient frequency to be demonstrable in the setting of a clinical trial or population study.
(3) Point Counter-Point [by invitation of Editors]
●Title: 10 words maximum.
●Word limit: 700 words maximum.
●Abstract: not required.
●Figures/ tables: 4 maximum.
●References: No limit.
●Figures: 2 maximum.
●Description: Balanced discussion of controversies in pathology.
(4) Letters to the Editor
●Word limit: 500 words maximum.
●Abstract: not required.
●References: No limit.
●Figures/ tables: 1 maximum.
●Description: Letters must offer perspective to content published in JDB. A Letter must reference the original source, and a Response to a Letter must reference the Letter in the first few paragraphs. Letters can use an arbitrary title, but a Response must cite the title of the Letter: e.g. Response to [title of Letter]. This ensures that readers can track the line of discussion. Authors to whom the letter type is referred for submission by the Editor are exempt in adherence to the scope of the letter type.
(5) Commentaries [by invitation of Editors]
●Word limit: 1,500 words maximum excluding references.
●Title: 20 words maximum.
●Abstract: not required.
●References: 20 maximum, including the article discussed.
●Figures/tables: 2 maximum.
●Description: Commentaries discuss a paper published in a specific issue and should set the problems addressed by the paper in the wider context of the field.
(6) Review Articles [by invitation of Editors]
●Word limit: 3000-5,000 words including abstract but excluding the highlights of the study (see 5. PREPARATION OF THE MANUSCRIPT, under Highlights), references, tables and figures
●Abstract: 250 words maximum, sub-headers are not required.
●References: no maximum.
●Figures/tables: minimum 1 image or figure, excluding the feature figure (see 5. PREPARATION OF THE MANUSCRIPT, under Feature Figure).
●Description: Reviews are comprehensive analyses of specific topics. They are submitted upon invitation by the Editors. Proposals for reviews may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration. Both solicited and unsolicited review articles will undergo peer review prior to acceptance.
(7) Research Letters
●Word limit: 800 words maximum but excluding the highlights of the study (see 5. PREPARATION OF THE MANUSCRIPT, under Highlights).
●Abstract: none.
●References: No limit.
●Figures/tables: 2 maximum, excluding the feature figure (see 5. PREPARATION OF THE MANUSCRIPT, under Feature Figure).
●Authors: 5 maximum; Other persons who have contributed to the study may be indicated in an Acknowledgement with their permission, including their academic degrees, affiliations, contribution to the study, and an indication if compensation was received for their role.
●Description: Research Letters should report original findings in an intermediate fashion between an abstract and an article. These submissions must not duplicate other material published or submitted for publication. In general, Research Letters should be divided into the following sections: To the Editor (which serves as an introduction), Methods, Results, and Comment. Research Letters considered for publication will undergo peer review.
(8) Editorials [by invitation of Editors]
●Word Limit: 1,500 words maximum.
●Abstract: not required.
●References: No limit.
●Description: Proposals for Editorials may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration.
(9) Rapid Publication
●Word limit: 700 words maximum.
●Abstract: not required.
● References: No limit.
●Figures: 2 maximum.
●Description: Rapid Communications are intended to disseminate information as quickly as possible due to the new research and information presented. They undergo one review only and no revisions are al-lowed unless very minor.
(10) Diabetes News [by invitation of Editors]
●Word limit: 500 words maximum.
●Abstract: not required.
●References: 5 maximum.
●Figures: 2 maximum.
●Proposals for Diabetes News may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration.
5. PREPARATION OF THE MANUSCRIPT
Pre-acceptance English-language editing
Authors for whom English is a second language may choose to have their manuscript professionally edited before submission to improve the English. Visit our site to learn about the options. All services are paid for and arranged by the author. Please note using the Wiley English Language Editing Service does not guarantee that your paper will be accepted by this journal.
Optimising Your Article for Search Engines
Many students and researchers looking for information online will use search engines such as Google, Yahoo or similar. By optimising your article for search engines, you will increase the chance of someone finding it. This in turn will make it more likely to be viewed and/or cited in another work. We have compiled these guidelines to enable you to maximise the web-friendliness of the most public part of your article.
Style of the Manuscript
Manuscripts must follow the style of the Vancouver agreement detailed in the International Committee of Medical Journal Editors’ revised Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication.
Author name: Each author’s name should be put in the following order:
First and Middle names (given name, capitalize the first letter of each name)
Last name (family name, surname, all letters should be capitalized)
Spelling: The journal uses US spelling and authors should therefore follow the latest edition of Merriam–Webster’s Collegiate Dictionary.
Units: All measurements must be given in SI or SI-derived units. For more information about SI units, please go to the Bureau International des Poids et Mesures (BIPM) website.
Abbreviations: Must be used sparingly – only where they ease the reader’s task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.
Trade names: Must be used sparingly – only where they ease the reader’s task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.